Amgen, Inc. (NASDAQ:AMGN) shares are trading lower by 4.11% to $237.51 during Monday's pre-market session following FDA approval of Bristol Myers Squibb Co's (NYSE:BMY) plaque psoriasis drug Sotyktu, which showed superior efficacy fo Amgen's Otezla.
What Happened?
The FDA approved Bristol Myers Squibb's Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Sotyktu is not recommended for use in combination with other potent immunosuppressants. The approval is based on the Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials...Read More
See Also: Why Akari Therapeutics Shares Are Getting Obliterated
According to data from Benzinga Pro, Amgen has a 52-week high of $258.45 and a 52-week low of $198.64.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
